Call for Proposals Open for the 2020 Global Congress on IP and the Public Interest
[Carolina Botero] We in Colombia are looking forward to welcoming you to Cartagena for the 6th Global Congress on IP and the Public Interest, August 13-15. From this week on the registry and call for session proposals is open! It includes the request for scholarships. We will have three main tracks on Medicines, Digital Rights, and Copyright Reforms and Open Policies. We will also have two cross-cutting tracks: Traditional Knowledge and Trade Agreements. Click here for more.
Joint Comment to WIPO on Copyright and Artificial Intelligence
[Comment endorsed by 16 members of the Global Expert Network on Copyright User Rights] We submit this comment in response to the World Intellectual Property Organization request in relation to its work on the impact of artificial intelligence (Al) on intellectual property (IP)… We comment here only on the copyright related questions in section 13. Some of our comments with regard to the framing of the questions and defining the differences between AI, machine learning and text and data mining may apply more broadly to the entire document. Click here for more.
See also: Matthew Sag. Does Copyright Require Authorization to Use Data “Subsisting in Copyright Works?” Link.
The Case for Disclosure of Original Biologics Manufacturing Information
[Yaniv Heled] Abstract: Ten years after the enactment of the Biologics Price Competition and Innovation Act (BPCIA), competition in biologics markets remains scant and far from sufficient for lowering prices of biologics to the level of 80-90% price drops seen in generic drug markets. This reality is not a result of one or two cardinal reasons, but many. If lowering the price of biologics is the goal and competition is the means by which we seek to achieve that goal, then there does not seem to be a quick fix to address all of the many impediments to competition that plague biologics markets. Yet, certain changes to how the Food and Drug Administration (FDA) evaluates and approves biologics may go a long way toward the creation of meaningful competition in biologics markets. One such change would be making original biologics’ manufacturing information available to follow-on manufacturers. Click here for more.
Reconstructing Rights: Project Synthesis and Recommendations
[P. Bernt Hugenholtz and Martin Kretschmer] Abstract: … This introductory chapter gives an overview of a collaborative research project (‘Reconstructing Rights’) that normatively examined the core economic rights protected under EU copyright law, with the aim of realigning these rights with economic and technological realities. Five ‘borderline’ cases are being examined to explore the implications of different theoretical models: (1) Digital Resale; (2) Private Copying; (3) Hyperlinking and Embedding; (4) Cable Retransmission; (5) Text and Data Mining. Click here for more.
Kerala MP Seeks Prime Minister’s Intervention for Domestic Production of TB Drugs Bedaquiline & Delamanid through Compulsory License
[PharmaBiz] A Member of Parliament from Kerala, TN Prathapan, has appealed to Prime Minister Narendra Modi to take immediate measures to initiate the domestic generic production of TB drugs bedaquiline and delamanid through compulsory license. In a letter to PM, the Kerala MP urged him to direct the Union health ministry to initiate steps to include both bedaquiline and delamanid in the National list of essential medicines (NLEM) and to put an end to dependency on drug donation as given India is among the highest TB burden countries in the world, the quantities of bedaqmlme and delamanid donated to the RNTCP are grossly inadequate to treat the drug-resistant TB (DR-TB) population in India. Click here for more on TWN.my.
WIPO and the US Copyright Office Examine Artificial Intelligence and, to Lesser Extent, Intellectual Property
[Andrés Izquierdo and Sean Flynn] On February 5, 2020, the U.S. Copyright Office and the World Intellectual Property Organization (WIPO) co-sponsored a well-attended event on Copyright in the Age of Artificial Intelligence (AI). The full-day event took an in-depth look at the development and operation of artificial intelligence (“AI”). It paid substantially less attention to the full range of intellectual property issues raised by this new field. Click here for more.
